Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mind Medicine (MindMed) Inc.

6.15
-0.3100-4.80%
Post-market: 6.160.0110+0.18%19:32 EDT
Volume:946.65K
Turnover:5.86M
Market Cap:464.64M
PE:-3.99
High:6.53
Open:6.46
Low:6.03
Close:6.46
Loading ...

Analysts Conflicted on These Healthcare Names: Mind Medicine (MNMD), RAPT Therapeutics (RAPT) and LifeMD (LFMD)

TIPRANKS
·
11 Mar

Mind Medicine’s (MNMD) Recent Achievements Boosting Stock

TIPRANKS
·
09 Mar

Mind Medicine Is Maintained at Outperform by Baird

Dow Jones
·
07 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mind Medicine (MNMD), SurModics (SRDX) and Enhabit, Inc (EHAB)

TIPRANKS
·
07 Mar

Mind Medicine Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder

Benzinga
·
06 Mar

BRIEF-MindMed FY Net Income USD -108.679 Million

Reuters
·
06 Mar

MindMed FY Basic EPS USD -1.54

THOMSON REUTERS
·
06 Mar

MindMed FY Operating Expenses USD 103.916 Million

THOMSON REUTERS
·
06 Mar

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Business Wire
·
06 Mar

MindMed to Present at Leerink’s Global Healthcare Conference 2025

Business Wire
·
04 Mar

Press Release: MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Dow Jones
·
20 Feb

Mind Medicine (MNMD) Advances Groundbreaking LSD Treatment

TIPRANKS
·
06 Feb

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Dow Jones
·
05 Feb

Mind Medicine doses first patient in Panorama study

TIPRANKS
·
30 Jan

Mind Medicine (MindMed) Inc - Topline Data Expected in Second Half of 2026

THOMSON REUTERS
·
30 Jan

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of Mm120 in Generalized Anxiety Disorder

THOMSON REUTERS
·
30 Jan

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Business Wire
·
30 Jan

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive
·
20 Jan